Brief: Arcus Biosciences And Summit Therapeutics Enter Into Clinical Trial Collaboration
22/07/2026 22:51
BRIEF-Arcus Biosciences And Summit Therapeutics Enter Into Clinical Trial Collaboration July 22 (Reuters) - Arcus Biosciences Inc RCUS.N:
ARCUS BIOSCIENCES AND SUMMIT THERAPEUTICS ENTER INTO CLINICAL TRIAL COLLABORATION TO EVALUATE CASDATIFAN COMBINED WITH IVONESCIMAB IN KIDNEY CANCER
ARCUS BIOSCIENCES INC: UNDER TERMS OF AGREEMENT, SUMMIT WILL SUPPLY IVONESCIMAB AND ARCUS WILL CONDUCT AND SPONSOR COMBINATION STUDY
ARCUS BIOSCIENCES INC: BOTH COS WILL CONTRIBUTE TO COST OF STUDY, EACH CO WILL RETAIN DEVELOPMENT & COMMERCIAL RIGHTS TO THEIR RESPECTIVE MOLECULES
ARCUS BIOSCIENCES INC: INITIAL DATA FROM THIS CLINICAL TRIAL COLLABORATION IS EXPECTED TO BE GENERATED BY MID-2027
Source text: ID:nBw5cyfqKa
Further company coverage: RCUS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)